It’s a big week for biotech in Utah! Salt-Lake City-based Recursion announced that the FDA approved the company’s Investigational New Drug application to start a Phase 1 study of REC-994 in cerebral cavernous malformation, a genetic disease that affects up to 1.5 million Americans.
Recursion has made headlines for their pioneering use of machine learning and artificial intelligence in discovering new drug candidates. The company uses an extensive proprietary database and aims to discover 100 drugs using AI/ML by 2025. Already, Recursion’s pipeline includes about 30 programs in various disease states.
As Recursion CEO Chris Gibson explained to MedCity News, REC-994 was discovered using machine learning. Read more